DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Ubicación actual:
>
> This Story


Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment

 

 

Business Affairs Homepage

Tech giants sign on to interoperability pledge Amazon, Google, IBM, Microsoft, Oracle, and Salesforce agree to common interest

Scottish radiologist shortage looming 'We are on red alert – there is absolutely no doubt about this'

GE Healthcare joins AdvaMed Access to global thought leadership and policy area expertise

In Korea and Italy, imaging OEMs face accusations of anti-competitive actions Are unfair tactics being used to hurt non-OEM equipment servicers?

Forces driving healthcare M&A activity Understanding why consolidation is going to continue

Boston Scientific to buy VENITI for $160 million Price may rise pending FDA approval of Vici Venous Stent

Sotera Health's Nordion closes sale of medical isotopes business to BWX Technologies About 150 employees will be transferred in the deal

FDA clears Aidoc AI solution for triaging head CT scans Flags acute intracranial hemorrhage cases by focusing on abnormal regions

Henry Ford Health System and GM enter "Direct to Employer" healthcare contract A first-of-its-kind arrangement for both organizations

Varian to acquire humediQ Global Bringing IDENTIFY automated workflow solution to surface-guided radiation therapy

DaVita hit with $383.5 million jury verdict in dialysis death suit

por Thomas Dworetzky , Contributing Reporter
A Denver jury has dropped a mile-high $383.5 million verdict on GranuFlo dialysis maker DaVita over the deaths of three patients who suffered cardiac arrests after getting GranuFlo dialysis therapy at DaVita clinics.

The families of the three deceased patients – Irma Menchaca, Gary Saldana and Deborah Hardin – were awarded $125 million in punitive damages and compensatory damages from $1.5 million to $5 million, according to a statement by firms representing the families of the patients, Hagens Berman and Paynter Law Firm.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“DaVita ignored many red flags that preceded the loss of life of these three patients and many others,” said lead trial attorney Rob Carey of Hagens Berman. “It is our mission now to fight for the rights of those who lost their lives due to DaVita’s abhorrent oversight and negligence.”

DaVita will appeal the case, according to Reuters.

“Our first priority is the safety of our patients,” DaVita said, according to news agency. “Our clinical outcomes – among the best in the industry – demonstrate our commitment to providing the highest level of care.”

In 2012, FDA put out a Class 1 recall for GranuFlo, warning clinicians that the excess acetate in GranuFlo could lead to high bicarbonate levels and metabolic alkalosis, which can lead to cardiopulmonary arrest and death. GranuFlo, made by Fresenius Medical Care, helps remove waste products and maintain proper pH balance in a patient’s blood, according to Reuters.

After the FDA recall, in 2013, Hagens Berman filed wrongful death suits charging that there were “several things DaVita could and should have done, but did not do, to protect its patients.” According to the legal complaints, the company “failed to inspect and review the composition of GranuFlo and notice changes,” and in addition, DaVita “should have noticed a significant upswing overall in bicarbonate blood levels when patients returned for dialysis treatments.”

The firm’s filings also state that the company should also have spotted the “uptick in reports of death and complications.”

The relationship between heart problems and dialysis was looked at in late 2016, researchers used MR to gain insight on the relationship.

In a University of Nottingham study, appearing in the Journal of the American Society of Nephrology, the scientists showed that the treatment could reduce blood flow and lead to permanent heart damage, whether the patients were on standard hemodialysis (HD) or hemodiafiltration (HDF).
  Pages: 1 - 2 >>

Business Affairs Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente su conciencia de marca
Subastas + ventas Privadas
Consigue el mejor precio
Comprar Equipo/Piezas
Encuentra El Precio Más Bajo
Noticias diarias
Lee las últimas noticias
Directorio
Examina todos los usuarios DOTmed
Ética en DOTmed
Ver nuestro programa de ética
El oro parte programa del vendedor
Recibir las solicitudes de PH
Programa de distribuidor con servicio gold
Recibe solicitudes
Proveedores de atención de salud
Ver todos los HCP (abreviatura de asistencia médica) Herramientas
Trabajos/Entrenamiento
Encontrar/rellenar un trabajo
Parts Hunter +EasyPay
Obtener presupuestos para piezas
Certificado recientemente
Ver usuarios certificados recientemente
Recientemente clasificado
Ver usuarios certificados recientemente
Central de alquiler
Alquila equipos por menos
Vende equipos/piezas
Obtén más dinero
Mantenga el foro de los técnicos
Buscar ayuda y asesoramiento
Petición sencilla de propuestas
Obtén presupuestos para equipos
Feria comercial virtual
Encuentra servicio para el equipo
El acceso y el uso de este sitio está conforme a los términos y a las condiciones de nuestro AVISO LEGAL & AVISO DE LA AISLAMIENTO
Característica de y propietario DOTmeda .com, inc. Copyright ©2001-2018 DOTmed.com, Inc.
TODOS LOS DERECHOS RESERVADOS